DJIA 17,678.23 -40.31 -0.23%
NASDAQ 4,863.36 -13.16 -0.27%
S&P 500 2,056.15 -4.90 -0.24%
market minute promo

Ophthotec (NASDAQ: OPHT)

47.03 -0.12 (-0.25%)

Quote as of

company name or ticker

Recent Quotes

OPHT $47.03 -0.25%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $46.59
Previous Close $47.15
Daily Range $46.01 - $47.76
52-Week Range $30.13 - $58.29
Market Cap $1.6B
P/E Ratio -15.98
Dividend (Yield) $0.00 (0.0%)
Volume 350,997
Average Daily Volume 272,999
Current FY EPS -$2.98



Ophthotec (OPHT) Description

Ophthotech Corp is a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the back of the eye with a focus on developing therapeutics for age-related macular degeneration. Website:

News & Commentary Rss Feed

3 Little-Known Stocks I'm Glad I Bought

Ophthotech Corp, Portola Pharmaceuticals Inc., and Insys Therapeutics Inc., have been top performers this past year.

2 Tiny Biotechs That Could Have Blockbuster Opportunity

Got risk tolerance? Check out these two small cap biotechs with huge potential.

Celgene Gains on Label Expansion of Revlimid in the EU - Analyst Blog

Ophthotech's (OPHT) CEO Dr. David Guyer on Q4 2014 Results - Earnings Call Transcript

Celgene Up on Hematology Drug Revlimid's Label Expansion - Analyst Blog

Can These Three BioTech Companies Make It Big?

Coronado Biosciences In-Licenses Revogenex's Pain Drug - Analyst Blog

Coronado Biosciences In-Licenses Revogenex's Pain Drug - Analyst Blog

Benzinga's Top Initiations

Alnylam Reports Narrower Loss in Q4, Focuses on Pipeline - Analyst Blog

Genomic Health Loss Narrower than Expected, Revenues Lag - Analyst Blog

See More OPHT News...